Regulation 30(5) of SEBI ( LODR), 2015 KMP''S authorised to determine materiality under Regulation 30(5) of SEBI (LODR), 2015
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited's Board meeting on May 12, 2026 resulted in multiple outcomes. Key appointment: Mr. Amit Mahla (formerly with JB Pharma) appointed as CEO, succeeding Mr. Umesh Manohar Kunte who resigned in December 2025. Financial performance declined significantly - FY26 revenue at Rs. 3,336 Crores vs Rs. 3,458 Crores in FY25, with the company reporting a net loss of Rs. 1.49 Crores compared to profit of Rs. 17.2 Crores in the prior year. The decline was driven by reduced revenues, increased finance costs, and significant inventory/property fair value losses. Statutory auditors issued an unmodified opinion. The Board recommended a final dividend of Rs. 5 per share (50%) for FY26, subject to shareholder approval at the AGM scheduled for August 6, 2026.
The appointment of an experienced pharma executive as CEO may provide positive sentiment, though the company faces near-term profitability challenges. Declining earnings and negative EPS despite dividend recommendation may create mixed signals for investors focused on growth versus income.